Considering this from Proactive investor....Fondaparinux, a generic version of GlaxoSmithKline’s Arixtra, is FDA approved and targets the multi-billion dollar heparin-drug market.
Multi Billion Dollar Heparin-drug market and we are scratching sround for a couple of mill. We really are getting right royally screwed from DRs. Let's hope we get some new blood in the company that can take these Indians to task.
- Forums
- ASX - By Stock
- TSN
- News: Alchemia Limited in halt relating to profit share for anti-coagulant drug
News: Alchemia Limited in halt relating to profit share for anti-coagulant drug, page-2
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add TSN (ASX) to my watchlist
|
|||||
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
NEWS
Exceptional lithium assays uncovered at Falcon Lake – expanding mineralisation, big potential ahead
NEWS
First paediatric clinical site activated – major recruitment milestone and key appointment announced
TSN (ASX) Chart |
Day chart unavailable